Who are Lu-177 DOTA-TATE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Detectnet, Pegvisomant/ Sandostatin LAR, somatostatin or terlipressin, Indium-111 pentetreotide, Sandostatin ® injection, Octreotide Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lu-177-dota-tate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lu-177 DOTA-TATE — Competitive Intelligence Brief

Lu-177 DOTA-TATE (Lu-177 DOTA-TATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Somatostatin receptor-targeting peptide. Area: Oncology.

phase 2 Somatostatin receptor-targeting peptide Somatostatin receptors Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lu-177 DOTA-TATE (Lu-177 DOTA-TATE) — AHS Cancer Control Alberta. Lu-177 DOTA-TATE is a radiolabeled peptide that targets somatostatin receptors on neuroendocrine tumors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lu-177 DOTA-TATE TARGET	Lu-177 DOTA-TATE	AHS Cancer Control Alberta	phase 2	Somatostatin receptor-targeting peptide	Somatostatin receptors
Detectnet	copper dotatate Cu-64	Radiomedix	marketed	Radioactive Diagnostic Agent [EPC]	somatostatin receptors, particularly SSTR2	2020-01-01
Pegvisomant/ Sandostatin LAR	Pegvisomant/ Sandostatin LAR	Pfizer	marketed	Growth hormone receptor antagonist (pegvisomant); somatostatin analog (octreotide LAR)	Growth hormone receptor (pegvisomant); somatostatin receptors, particularly SSTR2 and SSTR5 (octreotide)
somatostatin or terlipressin	somatostatin or terlipressin	National Science and Technology Council, Taiwan	marketed	Vasoactive peptide	Somatostatin receptors (SSTR) / Vasopressin V1 receptor
Indium-111 pentetreotide	Indium-111 pentetreotide	Radio Isotope Therapy of America	marketed	Radiolabeled somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)
Sandostatin ® injection	Sandostatin ® injection	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)
Octreotide Injection	Octreotide Injection	Centre Hospitalier Universitaire, Amiens	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-08-23 — Detectnet · 10383961 · US
2032-08-23 — Detectnet · 10159759 · US
2032-08-23 — Detectnet · 11160888 · US

Sponsor landscape (Somatostatin receptor-targeting peptide class)

AHS Cancer Control Alberta · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lu-177 DOTA-TATE — Competitive Intelligence Brief. https://druglandscape.com/ci/lu-177-dota-tate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab